Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and globally increases the adaptive immune response and results in an enhanced response to the cancer. In a subset of patients, this leads to longer Progression Free Survival (PFS), and in some cases remission. However, there is no companion diagnostic available to predict responders. The goal of this project is to develop a deep sequencing assay to measure the immune repertoire and a corresponding diagnostic protocol that differentiates ipilimumab responders from non-responders. Currently, while many of patients experience immune mediated side effects related to ipilimumab, less than 10% of patients? cancer responds to therapy. Developing a companion diagnostic that differentiates responders from non-responders would protect non-responders from unnecessary side-effects.

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research – Phase I (N43)
Project #
261201300037C-0-0-1
Application #
8752779
Study Section
Project Start
2013-09-12
Project End
2014-06-11
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$266,199
Indirect Cost
Name
Adaptive Tcr Corporation
Department
Type
DUNS #
832591544
City
Seattle
State
WA
Country
United States
Zip Code
98102